{"name":"atai Life Sciences","slug":"atai","ticker":"ATAI","exchange":"NASDAQ","domain":"atailifesciences.com","description":"atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.","hq":"Berlin, Germany / New York, NY","founded":0,"employees":"99","ceo":"Florian Brand","sector":"Psychedelic Medicine / Mental Health","stockPrice":4.06,"stockChange":-0.18,"stockChangePercent":-4.25,"marketCap":"$1.5B","metrics":{"revenue":3488000,"revenueGrowth":-38.7,"grossMargin":0,"rdSpend":400000,"netIncome":-149269000,"cash":230767008,"dividendYield":0,"peRatio":-8.1,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"psilocybin patent cliff ($0.00 at risk)","drug":"psilocybin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-01","type":"earnings","headline":"atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"atai Life Sciences reported its fourth quarter and full year 2022 financial results, highlighting progress in its clinical pipeline and partnerships.","drugName":"","sentiment":"neutral"},{"date":"2023-01-09","type":"deal","headline":"atai Life Sciences Announces Collaboration with the University of California, San Francisco (UCSF)","summary":"atai Life Sciences has entered into a collaboration with the University of California, San Francisco (UCSF) to advance the development of psychedelic-assisted therapies for mental health disorders.","drugName":"","sentiment":"positive"},{"date":"2022-11-14","type":"trial","headline":"atai Life Sciences Announces Positive Topline Results from Phase 2b Clinical Trial of Psilocybin-Assisted Therapy for Treatment-Resistant Depression","summary":"atai Life Sciences announced positive topline results from its Phase 2b clinical trial of psilocybin-assisted therapy for treatment-resistant depression.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNRXFQSzVHZ0tjdGRNNXExQjdVRWJIOWswNUNPZWFvMHM3X3pSX01PM0VEVENBSkVSOC10aTlNc29oejZqcGZkcE1QbWtWeXZxYk1DZmVCSXRya1pjRnBMbVlvNDJobzFzVTdJMDV3Wm5kMFFFakRUZm9UQnAtcERVWWlmOF82RE11T2JQYWhzV1E1YkE?oc=5","date":"2026-02-05","type":"deal","source":"The Motley Fool","summary":"5 Psychedelic Stocks to Buy Now - The Motley Fool","headline":"5 Psychedelic Stocks to Buy Now","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNTzRqMkZJVUxwdklmSDR0aHAxWTFLQ0l0bFlzTFZOdTZlTFd1NEdINnhMLTJEeFVlNml5Q1htSzRsbkFZdzVMSndKMzF0VkdkSDdtR3JQSzF5OW5EQW0xbjdITlQ0bGpEWWQ3MlppV0RuY1lGSURZSzJoajNHYnFJWXNSSQ?oc=5","date":"2025-11-05","type":"deal","source":"pharmaphorum","summary":"Psychedelic merger to create AtaiBeckley completes - pharmaphorum","headline":"Psychedelic merger to create AtaiBeckley completes","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBqcnVtUW80UURQM1U4VUVNby1FYlZucnVxTVVock1WLS1zU3hYdXBsRU5aQ0ViUEF6cWU3MkJaU3Fib0dYZ2o3X1F5MTZscWU5M0ZxT2dtbFFYejBlOHZwSEpyVHozVzVaSlREbkFBd2V0SG80aFg4?oc=5","date":"2025-10-24","type":"regulatory","source":"The Microdose | Substack","summary":"Breakthrough therapy designation for atai/Beckley 5-MeO-DMT drug; both ketamine and active placebo improve depression symptoms; and ketamine company to receive priority FDA review - The Microdose | Su","headline":"Breakthrough therapy designation for atai/Beckley 5-MeO-DMT drug; both ketamine and active placebo improve depression sy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNNkU2ampVeHNabXU1S2taakp5bVgtLU5mSlg0UUlPTHpGNy1sejVJSlBHNTBJVk5uVzJScDV4LXJFLVVBLW1mOGVfakZ3VmdhVlZyZVRjdmxGTHJnaG9sX1FONEJGWVlwUURkTW1maGNkcGVEQkZFV08zUWNQRHlKRVo5UlcyUUZ1SGFZSF83MW5PcDZhOHpZMg?oc=5","date":"2025-10-18","type":"regulatory","source":"TechStock²","summary":"ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion - TechStock²","headline":"ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWFA2alRGQWwxVWpIWmZ4WFdTamg4a2pXRkwyb1hWdzgzZzVFNmtTOEcxMnlOVDVJUzJlc28xYmlJUzdUU0h5aDluc3hwWGZkQm1OVW5ONmdkS3ExWFJYcHZkbXdhcTktdU1sWjhJbU93aGhJanlJOG5fVkNsTWJmTmMwb29ueF9vczlqNmlIVkhaU1RiaU85YXZVZnNlcUdfai1tdkNnVWpOUQ?oc=5","date":"2025-10-06","type":"pipeline","source":"NAI500","summary":"Investing in Psychedelic Stocks: A New Frontier in Mental Health Treatment - NAI500","headline":"Investing in Psychedelic Stocks: A New Frontier in Mental Health Treatment - NAI500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOczlpM3NhMlRwUGp1SkNtNnhZTTdTTl9YVzJQUXZLaVN2am94aGJPcXRhWV9jaHJpeUJaWk1VWEp2NGNnRzNrdXk5MmxWbGhUMFNmUWNjcDRJcjU5YThWZDQ2VDFrQ05RQVVfSWpIUEE3bU9pTHA4U1BtZTNwc0M4VEJqdXU5Ql8zN29CXzM4c24?oc=5","date":"2025-09-24","type":"trial","source":"Clinical Trials Arena","summary":"atai and Beckley’s psychedelic advances to pivotal TRD trial - Clinical Trials Arena","headline":"atai and Beckley’s psychedelic advances to pivotal TRD trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-17","type":"earnings","source":"simplywall.st","summary":"Atai Life Sciences Second Quarter 2025 Earnings: US$0.14 loss per share (vs US$0.36 loss in 2Q 2024) - simplywall.st","headline":"Atai Life Sciences Second Quarter 2025 Earnings: US$0.14 loss per share (vs US$0.36 loss in 2Q 2024)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPdTU4WFFQdXlReGVnLVBCSjl2TEdaS21yWmtWVTl1VVVyUktSZFFmbmpNQTNtendiOEJDQnZ3UUk1ZmtvazltOHpOUzRJeTF4QS1YcHhud21VVFVtRG1XYk5pMlMyVmgxNDJneldRSkxwZmhDd0Z1RDEzQjFyRWx6N2wzOHpab2lGTU4tN2ZJeEk2RmpWaE1zMFpDTkxkcUVKb3c?oc=5","date":"2025-07-28","type":"trial","source":"BioPharma Dive","summary":"Atai backs away from schizophrenia drug after trial failure - BioPharma Dive","headline":"Atai backs away from schizophrenia drug after trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQVjRxNUFHN3JuNTR6T1lyQm8wZUtxQUJQZDVVR3p6ZjhCaW1mUWJ5SktQOG9kTGxNRHlTb3UyeWpIRTZZZkk1VUYxQVU3cFJCMU9GUUUyb1pUZVZXdDhLbkwxNkxzeDlHQmloTTVvWVJYODdhbWFic0hIWmJmSTE2Qlp3?oc=5","date":"2025-07-06","type":"pipeline","source":"WSJ","summary":"The MAHA Movement Loves Psychedelics. Should Wall Street? - WSJ","headline":"The MAHA Movement Loves Psychedelics. Should Wall Street?","sentiment":"neutral"}],"patents":[{"drugName":"psilocybin","drugSlug":"psilocybin","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["MindMed","Field Trip Health","Cybin Inc."],"therapeuticFocus":["Depression","Anxiety","PTSD"],"financials":{"source":"sec_edgar+yahoo","revenue":308000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":308000,"period":"2024-12-31"},{"value":314000,"period":"2023-12-31"},{"value":314000,"period":"2023-12-31"},{"value":233000,"period":"2022-12-31"},{"value":233000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":400000,"rdSpendHistory":[{"period":"2025-12-31","value":53062000},{"period":"2024-12-31","value":55455000},{"period":"2023-12-31","value":62203000},{"period":"2022-12-31","value":74313000}],"sgaSpend":65088000,"operatingIncome":-113347000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-113347000},{"period":"2024-12-31","value":-102166000},{"period":"2023-12-31","value":-123026000},{"period":"2022-12-31","value":-144430000}],"netIncome":-149269000,"netIncomeHistory":[{"period":"2025-12-31","value":-660047000},{"period":"2024-12-31","value":-149269000},{"period":"2023-12-31","value":-40224000},{"period":"2022-12-31","value":-152385000}],"eps":-2.91,"epsHistory":[{"period":"2025-12-31","value":-2.91},{"period":"2024-12-31","value":-0.93},{"period":"2023-12-31","value":-0.25},{"period":"2022-12-31","value":-0.98}],"cash":85300000,"cashHistory":[{"period":"2025-12-31","value":85300000},{"period":"2024-12-31","value":17505000},{"period":"2023-12-31","value":45034000},{"period":"2022-12-31","value":190613000}],"totalAssets":159387000,"totalLiabilities":70722000,"totalDebt":2072000,"equity":221874000,"operatingCashflow":-102675000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-102675000},{"period":"2024-12-31","value":-82437000},{"period":"2023-12-31","value":-84118000},{"period":"2022-12-31","value":-104467000}],"capex":-10868000,"capexHistory":[{"period":"2025-12-31","value":-10868000},{"period":"2024-12-31","value":-95000},{"period":"2023-12-31","value":-590000},{"period":"2022-12-31","value":-1024000}],"freeCashflow":-113543000,"dividendsPaid":null,"buybacks":-6635000,"employees":99,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":25086000,"ebit":-544922000,"ebitda":-544586000,"period":"2025-12-31","revenue":1066000,"epsBasic":-1.73,"netIncome":-544813000,"rdExpense":15962000,"epsDiluted":-1.73,"grossProfit":null,"operatingIncome":-39353000},{"sga":14505000,"ebit":-60967000,"ebitda":-60734000,"period":"2025-09-30","revenue":749000,"epsBasic":-0.28,"netIncome":-61074000,"rdExpense":14680000,"epsDiluted":-0.28,"grossProfit":null,"operatingIncome":-28407000},{"sga":14900000,"ebit":-27389000,"ebitda":-27162000,"period":"2025-06-30","revenue":719000,"epsBasic":-0.14,"netIncome":-27729000,"rdExpense":11092000,"epsDiluted":-0.14,"grossProfit":null,"operatingIncome":-25245000},{"sga":10597000,"ebit":-25409000,"ebitda":-25193000,"period":"2025-03-31","revenue":1555000,"epsBasic":-0.15,"netIncome":-26431000,"rdExpense":11328000,"epsDiluted":-0.15,"grossProfit":null,"operatingIncome":-20342000},{"sga":11318000,"ebit":-38232000,"ebitda":-38007000,"period":"2024-12-31","revenue":-5000,"epsBasic":-0.24,"netIncome":-38958000,"rdExpense":18942000,"epsDiluted":-0.24,"grossProfit":null,"operatingIncome":-30357000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.06,"previousClose":4.24,"fiftyTwoWeekHigh":6.75,"fiftyTwoWeekLow":1.4,"fiftyTwoWeekRange":"1.395 - 6.75","fiftyDayAverage":3.92,"twoHundredDayAverage":4.29,"beta":0,"enterpriseValue":1286796288,"forwardPE":-8.1,"priceToBook":6.64,"priceToSales":427.09,"enterpriseToRevenue":368.92,"enterpriseToEbitda":-10.66,"pegRatio":0,"ebitda":-120710000,"ebitdaMargin":0,"freeCashflow":0,"operatingCashflow":0,"totalDebt":2000000,"debtToEquity":1,"currentRatio":10.02,"returnOnAssets":-33,"returnOnEquity":-378,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":14,"targetHighPrice":25,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.4,"institutionHeldPercent":38.8,"sharesOutstanding":366916896,"floatShares":297128090,"sharesShort":22819769,"shortRatio":3.33,"shortPercentOfFloat":6.2,"epsTrailing":-2.84,"epsForward":-0.5,"revenuePerShare":0.01,"bookValue":0.61,"officers":[{"age":47,"name":"Mr. Christian  Angermayer","title":"Co-Founder & Chairman of the Board"},{"age":56,"name":"Dr. Srinivas G. Rao M.D., Ph.D.","title":"Co-Founder, CEO & Executive Director"},{"age":57,"name":"Dr. Gerd G. Kochendoerfer Ph.D.","title":"Chief Operating Officer"},{"age":44,"name":"Mr. Ryan  Barrett J.D.","title":"Chief Legal & Business Officer"},{"age":58,"name":"Mr. Michael Eric Faerm","title":"Chief Financial Officer"},{"age":56,"name":"Ms. Anne  Johnson CPA","title":"Chief Accounting Officer"},{"age":55,"name":"Dr. Glenn  Short Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Dr. Jason  Awe Ph.D.","title":"Vice President of Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ataibeckley.com","phone":"332 282 0507"}}